Cover Image
市場調查報告書

細胞週期蛋白依賴性激酶9:開發中產品分析

Cyclin Dependent Kinase 9 - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 367841
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴性激酶9:開發中產品分析 Cyclin Dependent Kinase 9 - Pipeline Review, H2 2017
出版日期: 2017年11月07日 內容資訊: 英文 92 Pages
簡介

本報告提供以細胞週期蛋白依賴性激酶9為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴性激酶9 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bayer AG
  • Cyclacel Pharmaceuticals Inc
  • Eli Lilly and Company
  • Jyant Technologies Inc
  • Selvita SA
  • Tolero Pharmaceuticals Inc
  • Tragara Pharmaceuticals Inc
  • Vichem Chemie Research Ltd
  • ViroStatics srl

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1124TDB

Title:
Cyclin Dependent Kinase 9
(Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2017.

Summary:

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Cyclin-dependent kinase 9 (CDK9) is a cyclin-dependent kinase associated with P-TEFb. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with CDK9 and cyclin T, which suggested a possible involvement of this protein in AIDS.

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 26 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 4 and 12 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Central Nervous System, Metabolic Disorders and Respiratory which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Multiple Myeloma (Kahler Disease), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Lung Cancer, Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Leukemias, Mantle Cell Lymphoma, Neuroblastoma, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rheumatoid Arthritis, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Colorectal Cancer, Cystic Fibrosis, Epstein-Barr Virus (HHV-4) Infections, Gastric Cancer, Gliosarcoma, Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Pain, Laryngeal Cancer, Melanoma, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Simplexvirus (HSV) Infections, Uterine Cancer and Warts.

The latest report Cyclin Dependent Kinase 9 - Pipeline Review, H2 2017, outlays comprehensive information on the Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)
  • The report reviews Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
    • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
    • Astex Pharmaceuticals Inc
    • AstraZeneca Plc
    • Bayer AG
    • Cyclacel Pharmaceuticals Inc
    • Eli Lilly and Co
    • Jyant Technologies Inc
    • MEI Pharma Inc
    • Selvita SA
    • Tolero Pharmaceuticals Inc
    • Vichem Chemie Research Ltd
    • ViroStatics srl
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
    • alvocidib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alvocidib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-7519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atuveciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-5576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4573 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1251152 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCT-68127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CYC-065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FIT-039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2857785 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapacitabine + seliciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seliciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK9 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK9 for Inflammation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK9 for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cyclin Dependent Kinase 9 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK9 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-1287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voruciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-2370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
  • Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 23, 2017: Tolero Pharma To Present Preclinical Data for Cancer Drug Candidate TP-1287 for Myc-dependent Triple Negative Breast Cancer
      • Oct 05, 2017: Tolero Pharmaceuticals To Provide Update On alvocidib At 9th International Conference On Leukemia And Hematologic Oncology
      • Sep 26, 2017: Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer
      • Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
      • Jun 21, 2017: Tolero Pharmaceuticals to Expand Enrollment of Phase II Study of Alvocidib in MCL-1-Dependent AML into Europe
      • Jun 15, 2017: Tolero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting
      • May 08, 2017: Tolero Pharmaceuticals Appoints Robert Imani Vice President, Drug Development
      • Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib at AACR 2017
      • Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on Alvocidib's Prodrug, TP-1287, at AACR 2017
      • Apr 02, 2017: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
      • Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI
      • Nov 15, 2016: Tolero Pharmaceuticals to Present Progress of Leukemia Program at the 58th ASH Annual Meeting and Exposition
      • Sep 06, 2016: Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016
      • Sep 06, 2016: Cyclacel Pharmaceuticals presents preclinical data on CCT68127 at Childhood Cancer 2016
      • Aug 02, 2016: Cyclacel CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Astex Pharmaceuticals Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Bayer AG, H2 2017
  • Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by Jyant Technologies Inc, H2 2017
  • Pipeline by MEI Pharma Inc, H2 2017
  • Pipeline by Selvita SA, H2 2017
  • Pipeline by Tolero Pharmaceuticals Inc, H2 2017
  • Pipeline by Vichem Chemie Research Ltd, H2 2017
  • Pipeline by ViroStatics srl, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top